secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2023-10-31T23:59:59+00:00
Accession:  0001193125-23-267275
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.02, 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV reports Q3 net loss, $149M cash; FDA clarifies COMFORT studies; terminates Nestlé deal
--------------------------------------------------------------------------------

- FDA provided written feedback harmonizing COMFORT Toddlers/Children protocol design; COMFORT Toddlers uses same eligibility as EPITOPE (DBPCFC required).
- Cash $149.1M (Dec 31 2022: $209.2M); 9M 2023 net loss $61.5M ($0.65/share) vs $57.0M loss in 9M 2022.
- Terminated Nestlé collaboration (MAG1C atopy patch test) effective Oct 30, 2023; APTITUDE study ended; no further milestones.
- First COMFORT Toddlers subject enrollment expected Q1 2024; COMFORT Children start after VITESSE recruitment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312523267275/0001193125-23-267275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312523267275/d495430d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-267275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer